NovoCure (NVCR) Shares Outstanding (Diluted Average) (2018 - 2026)

NovoCure has disclosed Shares Outstanding (Diluted Average) across 9 years of filings, most recently posting $114.1 million for Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $114.1 million, up 3.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $114.1 million (up 3.51% YoY), and the FY2025 annual result was $111.5 million, up 3.37% from the prior year.
• Shares Outstanding (Diluted Average) came in at $114.1 million for Q1 2026 at NovoCure, up from $111.5 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $114.1 million in Q1 2026 to a low of $104.2 million in Q1 2022.
• The 5-year median for Shares Outstanding (Diluted Average) is $107.3 million (2024), against an average of $107.8 million.
• Across the five-year window, Shares Outstanding (Diluted Average) gained 0.85% in 2024 and advanced 3.93% in 2025, its largest moves.
• NovoCure's Shares Outstanding (Diluted Average) stood at $104.7 million in 2022, then gained by 1.65% to $106.4 million in 2023, then grew by 1.36% to $107.8 million in 2024, then gained by 3.37% to $111.5 million in 2025, then increased by 2.4% to $114.1 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $114.1 million (Q1 2026), $111.5 million (Q4 2025), and $111.9 million (Q3 2025), per Business Quant data.